Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275561 · ClinicalTrials.gov registry record · Phase 2
Topical Steroid Treatment for Eosinophilic Esophagitis
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00275561: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00275561 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00275561, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This was a randomized controlled trial of swallowed fluticasone vs. placebo for eosinophilic esophagitis. Eosinophilic esophagitis is an inflammatory condition in which the wall of the esophagus becomes filled with large numbers of eosinophils, a type of white blood cell. Patients who have this condition have difficulty in swallowing (dysphagia) solid food. Prior to treatment the patients had biopsies of their esophagus and took questionnaires regarding their symptoms. Treatment was given for 6 weeks, after which biopsies were taken from the esophagus to measure any changes in the tissue from before treatment. The primary endpoint was improvement in dysphagia as measured by the validated Mayo Dysphagia Questionaire. Secondary outcomes included partial symptom response, and histologic (tissue) response to treatment.
Interventions
- DRUG Placebo
- DRUG Fluticasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2005-11 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00275561
The ClinicalTrials.gov registry entry for NCT00275561 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00275561 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00275561 about?
NCT00275561 is a clinical study titled "Topical Steroid Treatment for Eosinophilic Esophagitis". This was a randomized controlled trial of swallowed fluticasone vs. placebo for eosinophilic esophagitis. Eosinophilic esophagitis is an inflammatory condition in which the wall of the esophagus becomes filled with large numbers of eosinophils, a type of white blood cell. Patients who have this cond...
What is the current status of trial NCT00275561?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2005-11. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00275561?
The interventions under investigation include: Placebo (DRUG), Fluticasone (DRUG).
Who is sponsoring clinical trial NCT00275561?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.